Grail, Inc.(US:GRAL)2026-02-19 23:00Financial Data and Key Metrics Changes - Fourth quarter revenue was $43.6 million, an increase of $5.3 million or 14% compared to Q4 2024 [19] - Full year total revenue reached $147.2 million, up 17% from 2024, with screening revenue of $138.6 million, a 28% increase [19][20] - U.S. Galleri revenue for 2025 was $136.8 million, a 26% increase over 2024 [20] - Net loss for Q4 2025 was $99.2 million, a 2% increase compared to Q4 2024, while the full year net loss improved by 80% to $408.4 million [21] - Non-GAAP adjusted gross profit for Q4 2025 was $23.1 million, a 29% increase year-over-year [22] Business Line Data and Key Metrics Changes - U.S. Galleri tests volume grew 36% to over 185,000 tests in 2025, with a prescriber base of approximately 17,000 providers, up 30% from the prior year [6][20] - Development services revenue decreased by 49% to $8.6 million for the full year [20] Market Data and Key Metrics Changes - The company reported a fourfold increase in cancer detection rates compared to standard care, with significant improvements in early-stage cancer detection [12][19] - The NHS-Galleri trial showed a reduction in stage 4 cancer diagnoses, although it did not meet the primary endpoint of statistically significant reduction in combined stage 3 and 4 cancers [11][12] Company Strategy and Development Direction - The company plans to expand its field sales and medical team to drive commercial momentum based on strong trial results [5][6] - The completion of the PMA submission to the FDA marks a critical step in making Galleri available to more people [7][16] - The company aims to leverage new federal laws for Medicare coverage of FDA-approved multi-cancer early detection tests [8][27] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong commercial growth and the potential for Galleri to significantly impact cancer mortality rates [4][26] - The company reiterated guidance for Galleri sales growth of 22%-32% and cash burn for 2026 to be no more than $300 million [25] Other Important Information - The company ended the quarter with a cash position of $904.4 million, which includes proceeds from equity placements [22][23] - The company is focused on expanding awareness of multi-cancer early detection and differentiating Galleri's performance [7] Q&A Session Summary Question: Will the FDA approval decision be impacted by missing the stage shift endpoint? - Management confirmed that the FDA will focus on clinical performance and safety, and does not expect the NHS-Galleri study's results to negatively impact the approval [29] Question: How does the NHS-Galleri trial impact the Medicare REACH study? - Management indicated that the REACH study's primary endpoint is stage four reduction, which aligns with the favorable trends observed in the NHS-Galleri trial [31] Question: What is the strategy for expanding Galleri internationally? - Management believes the strong data from the NHS-Galleri trial will be compelling for discussions with other countries, although specific conversations have not yet begun [35][36] Question: What is the probability of FDA approval unchanged due to the NHS Galleri readout? - Management stated that the probability remains unchanged, emphasizing the compelling clinical benefits observed [44][46] Question: What are the next steps regarding the NHS and the multi-cancer early detection study? - Management has ongoing conversations with the NHS and anticipates that they will want to see full results before engaging in meaningful discussions [59][60]